Novolog Innolet is a drug owned by Novo Nordisk Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 21, 2021. Details of Novolog Innolet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
USRE41956 (Pediatric) | Dose setting limiter |
Jul, 2021
(3 years ago) |
Expired
|
| USRE41956 | Dose setting limiter |
Jan, 2021
(3 years ago) |
Expired
|
|
US5866538 (Pediatric) | Insulin preparations containing NaCl |
Dec, 2017
(7 years ago) |
Expired
|
| US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(7 years ago) |
Expired
|
|
US5618913 (Pediatric) | Insulin analogues |
Dec, 2014
(10 years ago) |
Expired
|
| US5618913 | Insulin analogues |
Jun, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Novolog Innolet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Innolet's family patents as well as insights into ongoing legal events on those patents.
Novolog Innolet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Novolog Innolet's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 21, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Novolog Innolet Generics:
There are no approved generic versions for Novolog Innolet as of now.
Alternative Brands for Novolog Innolet
There are several other brand drugs using the same active ingredient (Insulin Aspart Recombinant) as Novolog Innolet. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
|
About Novolog Innolet
Novolog Innolet is a drug owned by Novo Nordisk Inc. Novolog Innolet uses Insulin Aspart Recombinant as an active ingredient. Novolog Innolet was launched by Novo Nordisk Inc in 2013.
Approval Date:
Novolog Innolet was approved by FDA for market use on 31 October, 2013.
Active Ingredient:
Novolog Innolet uses Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Recombinant ingredient
Dosage:
Novolog Innolet is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300 UNITS/3ML (100 UNITS/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |